Mylotarg (Gemtuzumab Ozogamicin)

Gemtuzumab ozogamicin is an antibody‑drug conjugate that binds to the CD33 antigen on myeloid leukemia cells. After binding, the complex is internalized, releasing a calicheamicin derivative that creates DNA double‑strand breaks, leading to programmed cell death of the malignant cells.

The dose of Mylotarg is individualized by the prescribing physician based on the patient’s disease status, body surface area, and treatment protocol. Specific dosing regimens are determined by clinical guidelines and the treating oncologist.

Safety data for Mylotarg in pregnancy and lactation are limited. It is generally advised to avoid use in pregnant or breastfeeding women unless the potential benefit justifies the potential risk to the fetus or infant.

To order Mylotarg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and necessary import documentation.

Standard chemotherapy for AML relies on cytotoxic agents that affect rapidly dividing cells. Mylotarg adds a targeted approach by delivering a cytotoxic payload directly to CD33‑expressing leukemia cells, potentially enhancing efficacy while allowing lower doses of conventional chemotherapy.

Mylotarg should be stored at 2‑8 °C in a refrigerator, protected from light. The lyophilized powder must not be frozen or shaken. Before use, reconstitute according to the product label and keep the solution refrigerated if not administered immediately.

Mylotarg is supplied as a lyophilized powder that is reconstituted with a suitable diluent to form an infusion solution. It is administered intravenously over a specified period under medical supervision, typically as part of a combination chemotherapy schedule.

The most serious risks include veno‑occlusive disease of the liver, severe infections due to myelosuppression, and significant bleeding events. Patients should be closely monitored for hepatic dysfunction, signs of infection, and abnormal coagulation parameters throughout treatment.

Mylotarg should not be used in patients with known hypersensitivity to gemtuzumab ozogamicin or any of its excipients, in individuals with active uncontrolled infections, or in pregnant women unless the benefits outweigh the risks. Caution is also advised for patients with pre‑existing liver disease.